TABLE 3.
The impacts of definitive antimicrobial regimens on the mortality of patients with CRE-BSI
| Antimicrobial regimena | No. of deceased patients/total no. of patients (%) | Logistic regression |
|||
|---|---|---|---|---|---|
| Univariate |
Multivariate |
||||
| OR (95% CI) | P value | Adjusted OR (95% CI)b | P value | ||
| CAZ-AVI | 3/13 (23.1) | Reference | Reference | ||
| CAZ-AVI + tigecycline | 2/13 (15.4) | 0.606 (0.083–4.405) | 0.621 | 1.645 (0.106–25.422) | 0.722 |
| CAZ-AVI + tigecycline + polymyxin B sulfate | 1/9 (11.1) | 0.417 (0.036–4.813) | 0.483 | 0.606 (0.016–23.056) | 0.788 |
| Other regimens | 72/152 (47.4) | 3.000 (0.794–11.331) | 0.105 | 12.407 (1.684–31.430) | 0.011 |
| Tigecycline + polymyxin B sulfate | 19/46 (41.3) | 2.346 (0.568–9.679) | 0.238 | 13.674 (1.160–26.148) | 0.040 |
| Carbapenem + tigecycline + polymyxin B sulfate | 16/44 (36.4) | 1.905 (0.456–7.951) | 0.377 | 8.295 (1.041–16.123) | 0.046 |
| Carbapenem + polymyxin B sulfate + aminoglycoside | 5/13 (38.5) | 2.083 (0.378–11.482) | 0.399 | 13.564 (1.160–26.148) | 0.038 |
| Carbapenem + tigecycline | 11/14 (78.6) | 7.222 (1.444–16.444) | 0.016 | 29.810 (1.835–69.751) | 0.037 |
| Tigecycline | 13/19 (68.4) | 12.222 (1.990–25.060) | 0.007 | 33.121 (3.322–69.322) | 0.005 |
| Carbapenem + aminoglycoside | 8/16 (50.0) | 3.333 (0.660–16.847) | 0.145 | 24.250 (1.989–52.579) | 0.012 |
a
CAZ-AVI, ceftazidime-avibactam.
b
Adjusted for Pitt score, meropenem MIC of ≥8 mg/liter, immunocompromised status, source control of infection, and appropriate empirical therapy.